New Results From COSMIC-HF Presented At AHA 2019 Show Treatment Of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral Or Improved Measures Of Diastolic Function| Amgen
Amgen, Cytokinetics, and Servier presented Phase 2 trial results for omecamtiv mecarbil, showing neutral or improved diastolic function in heart failure patients. The drug increased systolic ejection time without reducing diastolic filling time. Omecamtiv mecarbil is in Phase 3 trials for heart failure with reduced ejection fraction.
How this was made
The 30-second read
Why it matters
The data suggest safety and functional neutrality, which is a key step toward Phase 3 and may influence investor sentiment.
Market read
New trial data are a primary catalyst for both companies, likely prompting short‑term price moves.
What to watch
Regulatory timeline and reimbursement landscape for heart‑failure drugs remain uncertain.
Background
The press release announces Phase 2 data for omecamtiv mecarbil, a cardiac myosin activator being co‑developed by Amgen and Cytokinetics.
Ticker impact
Amgen disclosed new Phase 2 COSMIC-HF trial results for omecamtiv mecarbil, showing neutral or improved diastolic function measures.
likely upward pressure as investors price in reduced safety concerns and potential efficacy.
Phase 2 data are material for a late‑stage cardiac drug; market typically reacts favorably to neutral or improving safety signals.
Cytokinetics, co‑developer of omecamtiv mecarbil, reported the same COSMIC-HF Phase 2 results, highlighting no worsening of diastolic function.
likely upward pressure as the partner benefits from the drug's continued development.
As a smaller biotech, CYTK is more sensitive to trial outcomes; neutral safety data are viewed as a catalyst.
Market effects
strengthens the cardiac‑failure therapeutic segment and may boost peer biotech valuations.
U.S. biotech sector could see modest gains.
Adds confidence to global cardiac‑myosin activator pipeline.
Counterpoint
If later Phase 3 fails to show efficacy, early optimism could reverse sharply.
Key entities
- CompanyAmgen
US‑listed biotech (NASDAQ: AMGN) leading the development.
- CompanyCytokinetics
US‑listed partner (NASDAQ: CYTK) co‑developer of the drug.
